Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial)

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 1000-1009

  Samri, Assia ^a,b,c   Roque Afonso, Anne Marie ^c,e   Beran, Ondrej ^a,b   Tateo, Mariagrazia ^c,d,e   Teicher, Elina ^d   Feray, Cyrille ^c   Sebagh, Mylène ^c,d,e   Guettier, Catherine ^c,d,e   Dussaix, Elisabeth ^c,d,e   Vittecoq, Daniel ^c,d,e   Samuel, Didier ^c,d,e   Autran, Brigitte ^a,b,f   Duclos Vallée, Jean Charles ^c,d,e  

^a Laboratoire d'Immunologie Cellulaire et Tissulaire CNRS URA 625   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anti HCV immune response; Anti HCV therapy; HCV recurrence; HIV HCV coinfection; Liver transplantation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DIDANOSINE; EFAVIRENZ; GAMMA INTERFERON; LAMIVUDINE; LOPINAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; EX VIVO STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; MIXED INFECTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CARCINOMA, HEPATOCELLULAR; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 71849094920     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.031     Document Type: Article

References (33)

1. Mauss S., and Rockstroh J.K. HCV/HIV-coinfection-is there a state of the art after APRICOT and RIBAVIC?. J Antimicrob Chemother 56 (2005) 615-618
2. Benhamou Y., Di Martino V., Bochet M., Colombet G., Thibault V., Liou A., et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
3. Rosenthal E., Poiree M., Pradier C., Perronne C., Salmon-Ceron D., Geffray L., et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17 (2003) 1803-1809
4. Pineda J.A., Romero-Gomez M., Diaz-Garcia F., Giron-Gonzalez J.A., Montero J.L., Torre-Cisneros J., et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41 (2005) 779-789
5. Egger M., May M., Chene G., Phillips A.N., Ledergerber B., Dabis F., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
6. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277 (1997) 112-116 [comment 33]
7. de Vera M.E., Dvorchik I., Tom K., Eghtesad B., Thai N., Shakil O., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 6 (2006) 2983-2993
8. Duclos-Vallee J.C., Feray C., Sebagh M., Teicher E., Roque-Afonso A.M., Roche B., et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47 (2008) 407-417
9. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 (2000) 578-582
10. Schulze zur Wiesch J., Lauer G.M., Day C.L., Kim A.Y., Ouchi K., Duncan J.E., et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175 (2005) 3603-3613
11. Shoukry N.H., Cawthon A.G., and Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Ann Rev Microbiol 58 (2004) 391-424
12. Valiante N.M., D'Andrea A., Crotta S., Lechner F., Klenerman P., Nuti S., et al. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 174 (2000) 77-89
13. Rosen H.R., Miner C., Sasaki A.W., Lewinsohn D.M., Conrad A.J., Bakke A., et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35 (2002) 190-198
14. Graham C.S., Baden L.R., Yu E., Mrus J.M., Carnie J., Heeren T., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
15. Rosen H.R., Hinrichs D.J., Gretch D.R., Koziel M.J., Chou S., Houghton M., et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117 (1999) 926-932
16. Weston S.J., Leistikow R.L., Reddy K.R., Torres M., Wertheimer A.M., Lewinsohn D.M., et al. Reconstitution of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology 41 (2005) 72-81
17. Schirren C.A., Jung M.C., Worzfeld T., Mamin M., Baretton G., Gerlach J.T., et al. Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. J Infect Dis 183 (2001) 1187-1194
18. Lauer G.M., Nguyen T.N., Day C.L., Robbins G.K., Flynn T., McGowan K., et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 76 (2002) 2817-2826
19. Alatrakchi N., Di Martino V., Thibault V., and Autran B. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 16 (2002) 713-717
20. Valdez H., Carlson N.L., Post A.B., Asaad R., Heeger P.S., Lederman M.M., et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 16 (2002) 1113-1118
21. Alatrakchi N., Graham C.S., He Q., Sherman K.E., and Koziel M.J. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis 191 (2005) 702-709
22. Kamal S.M., Graham C.S., He Q., Bianchi L., Tawil A.A., Rasenack J.W., et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 189 (2004) 1140-1150
23. Morice Y., Roulot D., Grando V., Stirnemann J., Gault E., Jeantils V., et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 82 (2001) 1001-1012
24. Teicher E., Vincent I., Bonhomme-Faivre L., Abbara C., Barrail A., Boissonnas A., et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 46 (2007) 941-952
25. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
26. Panel I. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 25 (1997) 658-663
27. Martin-Carbonero L., Benhamou Y., Puoti M., Berenguer J., Mallolas J., Quereda C., et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 38 (2004) 128-133
28. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112 (1997) 1017-1021
29. Meier V., Burger E., Mihm S., Saile B., and Ramadori G. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol 69 (2003) 50-58
30. Alatrakchi N., Di Martino V., Thibault V., Benhamou Y., Katlama C., Poynard T., et al. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS 18 (2004) 121-123
31. Rehermann B., Chang K.M., McHutchison J.G., Kokka R., Houghton M., and Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98 (1996) 1432-1440
32. Lauer G.M., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79 (2005) 12979-12988
33. Tsai S.L., Sheen I.S., Chien R.N., Chu C.M., Huang H.C., Chuang Y.L., et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 10 (2003) 120-135